Moderna investors should brace for more whiplash

Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.

Moderna Stock Sinks 18%—How Much More Can It Fall?

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, ...
24/7 Wall St.

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?

So, right now, is Moderna a buy on the dip? It's important to keep in mind that the stock still has climbed more than 500% ...

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with ...
24/7 Wall St.

Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

A late-stage melanoma vaccine report that was posted online and quickly pulled is driving a violent repricing in Moderna ...

Moderna’s stock tumbles after reported leak of data for cancer vaccine

Moderna and Merck are expected to share the Phase 3 data for their experimental cancer vaccine this weekend at a medical ...
CNBC

Biotech stocks are surging. How investors can play the new drug innovation boom

Moderna gave investors a scare as its stock plunged on Thursday. But it's still one of the hottest biotechs this year. And it's hardly alone – the sector is on a roll and looks poised for more gains ...